VEGF, CA153, and CEA levels decreased significantly after 6 months of SHD treatment (P < 0.01), illustrating that endocrine treatment combined with SHD can significantly improve the curative effect and may provide a better prognosis for patients with breast cancer. This evidence concerns the gene CEACAM5 and breast cancer.